Update on redemption of Secured, Unlisted, Redeemable, Non-Convertible Debentures
As filed · Strides Pharma Science Limited has informed the Exchange about Update on redemption of Secured, Unlisted, Redeemable, Non-Convertible Debentures
What happened
FactStrides Pharma Science Limited has redeemed the remaining outstanding Non-Convertible Debentures (NCDs) amounting to Rs. 24.20 Crores, along with applicable interest, as of March 31, 2025. Following this redemption, the company has no outstanding NCDs. This update follows previous communications regarding the partial redemption of NCDs.
Why it matters
CapitSignal interpretationRaising capital changes the share count or the debt load, and the stated use of proceeds is a commitment that can later be checked.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEBITDA to PAT conversion at ~50%+
We expect gross margins to remain in the 58-60% range.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Instrument and amount finally raised
- Stated use of proceeds
- Whether the enabling resolution is actually used
- Aspire to focus on North America Business Revenue of ~$375m by FY28 despite current external headwinds (management committed by FY28)
- Continue to add new customers in Europe by leveraging strong commercial presence and robust supply chain (management committed by FY27)
Evidence
- Strides Pharma Science Limited has informed the Exchange about Update on redemption of Secured, Unlisted, Redeemable, Non-Convertible Debentures(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- FUNDRAISE base 58; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%